Inventor · disambiguated record
Lawrence Klein
Also filed as: KLEIN LAWRENCE · KLEIN LAWRENCE W
36 granted patents·17 pending applications·161 citations·filing 1987–2025
97Inventor score
Files withCRISPR THERAPEUTICS AG32ECONOMIC ALCHEMY INC8VERTEX PHARMA5KLEIN LAWRENCE W2CASEBIA THERAPEUTICS LTD LIABILITY PARTNERSHIP1
Top patents by PatentIndex Score
53 records- 0198US11191783B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Dec 7, 2021·6 cites·19 claims
- 0298US11166985B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Nov 9, 2021·10 cites·14 claims
- 0398US11135247B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Oct 5, 2021·6 cites·20 claims
- 0498US11071755B1Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted Jul 27, 2021·7 cites·24 claims
- 0598US11013767B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2020·Granted May 25, 2021·5 cites·13 claims
- 0698US10736919B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Aug 11, 2020·13 cites·11 claims
- 0797US11207351B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Dec 28, 2021·3 cites·20 claims
- 0897US10881689B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Jan 5, 2021·7 cites·29 claims
- 0997US10857184B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Dec 8, 2020·9 cites·7 claims
- 1097US10729725B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2019·Granted Aug 4, 2020·7 cites·29 claims
- 1195US11298378B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Apr 12, 2022·2 cites·29 claims
- 1295US11202802B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Dec 21, 2021·2 cites·19 claims
- 1394US11559588B2Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Granted Jan 24, 2023·12 cites·18 claims
- 1494US11080789B1Methods and systems to quantify and index correlation risk in financial markets and risk management contracts thereonEconomic Alchemy LLC·Filed 2020·Granted Aug 3, 2021·18 cites·20 claims
- 1593US11471491B1Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2021·Granted Oct 18, 2022·1 cites·18 claims
- 1690US11587172B1Methods and systems to quantify and index sentiment risk in financial markets and risk management contracts thereonECONOMIC ALCHEMY INC·Filed 2012·Granted Feb 21, 2023·9 cites·18 claims
- 1790US11551305B1Methods and systems to quantify and index liquidity risk in financial markets and risk management contracts thereonECONOMIC ALCHEMY INC·Filed 2020·Granted Jan 10, 2023·2 cites·20 claims
- 1889US11622977B2Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2018·Granted Apr 11, 2023·1 cites·25 claims
- 1988US2023302053A1Materials and methods for engineering cells and uses thereof in immuno-oncologyCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 2087US11593886B1Methods and systems to quantify and index correlation risk in financial markets and risk management contracts thereonECONOMIC ALCHEMY INC·Filed 2021·Granted Feb 28, 2023·1 cites·20 claims
- 2186US11459587B2Materials and methods for treatment of pain related disordersVERTEX PHARMA·Filed 2017·Granted Oct 4, 2022·3 cites·17 claims
- 2282US12373890B1Methods and systems to quantify and index correlation risk in financial markets and risk management contracts thereonECONOMIC ALCHEMY INC·Filed 2023·Granted Jul 29, 2025·0 cites·20 claims
- 2382US11941645B1Methods and systems to extract signals from large and imperfect datasetsECONOMIC ALCHEMY INC·Filed 2023·Granted Mar 26, 2024·0 cites·20 claims
- 2481US11599892B1Methods and systems to extract signals from large and imperfect datasetsECONOMIC ALCHEMY INC·Filed 2012·Granted Mar 7, 2023·2 cites·18 claims
- 2580US11854083B1Methods and systems to quantify and index liquidity risk in financial markets and risk management contracts thereonECONOMIC ALCHEMY INC·Filed 2022·Granted Dec 26, 2023·0 cites·23 claims
- 2679US12442020B2Materials and methods for treatment of pain related disordersVERTEX PHARMA·Filed 2022·Granted Oct 14, 2025·0 cites·18 claims
- 2779US11427838B2Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disordersVERTEX PHARMA·Filed 2017·Granted Aug 30, 2022·1 cites·6 claims
- 2879US8326748B1Automated loan approval systemKLEIN LAWRENCE·Filed 2010·Granted Dec 4, 2012·5 cites·14 claims
- 2976US11174469B2Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disordersCRISPR THERAPEUTICS AG·Filed 2017·Granted Nov 16, 2021·1 cites·11 claims
- 3076US7742980B1Automated loan approval systemIMX INC·Filed 2002·Granted Jun 22, 2010·15 cites·14 claims
- 3176US2025166076A1Methods and systems to quantify and index liquidity risk in financial markets and risk management contracts thereonECONOMIC ALCHEMY INC·Filed 2025·Application pending·0 cites
- 3275US2024318200A1Compositions and methods for gene editingCRISPR THERAPEUTICS AG·Filed 2024·Application pending·0 cites
- 3375US2024066150A1Materials and methods for treatment of pain related disordersVERTEX PHAMACEUTICALS INCORPORATED·Filed 2023·Application pending·0 cites
- 3470US2023227855A1Materials and Methods for Treatment of Myotonic Dystrophy Type 1 (DM) and Other Related DisordersVERTEX PHARMA·Filed 2022·Application pending·0 cites
- 3570US2023330270A1Materials and methods for treatment of friedreich ataxia and other related disordersCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 3669US2022364082A1Compositions and methods for editing the angiopoietin-like 4 (angptl4) geneCRISPR THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 3767US2022340897A1Materials and methods for treatment of apolipoprotein c3 (apociii)-related disordersCRISPR THERAPEUTICS AG·Filed 2022·Application pending·0 cites
- 3860US11920148B2Compositions and methods for gene editingCRISPR THERAPEUTICS AG·Filed 2018·Granted Mar 5, 2024·0 cites·18 claims
- 3959US11801313B2Materials and methods for treatment of pain related disordersVERTEX PHARMA·Filed 2017·Granted Oct 31, 2023·0 cites·10 claims
- 4059US11564997B2Materials and methods for treatment of friedreich ataxia and other related disordersCRISPR THERAPEUTICS AG·Filed 2017·Granted Jan 31, 2023·0 cites·14 claims
- 4155US2019185849A1Compositions and methods for gene editingCRISPR THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 4254US2022008473A1Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancerCRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 4352US2020123570A1Materials and methods for treatment of apolipoprotein c3 (apociii)-related disordersCRISPR THERAPEUTICS AG·Filed 2017·Application pending·0 cites
- 4446US11407997B2Materials and methods for treatment of primary hyperoxaluria type 1 (PH1) and other alanine-glyoxylate aminotransferase (AGXT) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Granted Aug 9, 2022·0 cites·15 claims
- 4545US2018127786A1Compositions and methods for gene editingCASEBIA THERAPEUTICS LTD LIABILITY PARTNERSHIP·Filed 2017·Application pending·0 cites
- 4645US2020248168A1Compositions and methods for treatment of proprotein convertase subtilisin/kexin type 9 (pcsk9)-related disordersCRISPR THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 4744US2020216857A1Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 4844US2020095579A1Materials and methods for treatment of merosin-deficient cogenital muscular dystrophy (mdcmd) and other laminin, alpha 2 (lama2) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 4943US2020040061A1Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disordersCRISPR THERAPEUTICS AG·Filed 2018·Application pending·0 cites
- 5042US5028144ABrake fluid testing deviceKLEIN LAWRENCE W·Filed 1989·Granted Jul 2, 1991·9 cites·23 claims
Showing the top 50 of 53 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Lawrence Klein files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →